Innate Pharma (IPHA) Long-Term Deferred Tax (2018 - 2024)
Innate Pharma's (IPHA) quarterly Long-Term Deferred Tax came in at $9.8 million in Q2 2024, down 6.74% YoY from $10.5 million in Q3 2023, and up 1.39% on a QoQ basis from $9.7 million in Q4 2023.
Innate Pharma (IPHA) Long-Term Deferred Tax (2018 - 2024) Analysis & Trends
Innate Pharma (IPHA) has 7 years of Long-Term Deferred Tax data on file, last reported at $9.8 million in Q2 2024.
- Quarterly Long-Term Deferred Tax fell 6.74% year-over-year to $9.8 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $9.8 million (down 6.74% YoY) and the FY2023 annual result came in at $9.7 million, up 10.85% from the prior year.
- Long-Term Deferred Tax rose to $9.8 million in Q2 2024, from $9.7 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $1.3 billion in Q2 2020 to a low of $5.8 million in Q4 2021.
- A 5-year average of $148.5 million and a median of $8.7 million in 2022 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2020 — Long-Term Deferred Tax soared 493.61% — and 2021, when it slumped 99.49%.
- Tracing IPHA's Long-Term Deferred Tax over 5 years: stood at $8.4 million in 2020, then sank by 31.93% to $5.8 million in 2021, then surged by 51.98% to $8.7 million in 2022, then grew by 10.85% to $9.7 million in 2023, then increased by 1.39% to $9.8 million in 2024.
- The last three Long-Term Deferred Tax figures came in at $9.8 million (Q2 2024), $9.7 million (Q4 2023), and $10.5 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 9.82 Mn |
| Dec 31, 2023 | 9.69 Mn |
| Jun 30, 2023 | 10.53 Mn |
| Dec 31, 2022 | 8.74 Mn |
| Jun 30, 2022 | 8.30 Mn |
| Dec 31, 2021 | 5.75 Mn |
| Jun 30, 2021 | 6.50 Mn |
| Dec 31, 2020 | 8.45 Mn |
| Jun 30, 2020 | 1.27 Bn |
| Dec 31, 2019 | 1.42 Mn |
| Dec 31, 2018 | 1.78 Mn |